Clinical Trials
25 trialsNCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT05255653 2026-05-15
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT07001748 2026-05-15
STOPGAP II
Eastern Cooperative Oncology Group
Phase 2/3 Recruiting
NCT07219238 2026-05-05
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
GE Healthcare
Phase 2/3 Recruiting
NCT07472140 2026-03-16
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07319429 2026-03-13
FEMUS
Fudan University
Phase 2/3 Recruiting
NCT07298642 2025-12-23
Extended-field Proton Therapy for Cervical Cancer
National Taiwan University Hospital
Phase 2/3 Recruiting
NCT03651206 2025-12-19
ROCSAN
ARCAGY/ GINECO GROUP
Phase 2/3 Recruiting
NCT06851663 2025-12-08
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Phase 2/3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05381597 2025-11-28
5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer
Boston University
Phase 2/3 Recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05770102 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT05316467 2025-08-11
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Fudan University
Phase 2/3 Recruiting
NCT05316935 2025-08-11
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
Fudan University
Phase 2/3 Recruiting
NCT06379113 2025-08-11
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
Fudan University
Phase 2/3 Recruiting
NCT06791460 2025-03-18
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3 Recruiting
NCT06123884 2025-02-10
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS â¥1) Cervical Cancer
Bio-Thera Solutions
Phase 2/3 Recruiting
NCT06288373 2024-10-30
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Tongji Hospital
Phase 2/3 Recruiting
NCT03755739 2024-06-25
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 2/3 Recruiting
NCT05797831 2024-05-02
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc.
Phase 2/3 Recruiting
NCT06341907 2024-04-02
Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC
Second Affiliated Hospital of Wenzhou Medical University
Phase 2/3 Recruiting
NCT03458221 2023-04-18
STAPOVER
Gynaecologisch Oncologisch Centrum Zuid
Phase 2/3 Recruiting
NCT03463252 2021-09-13
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
West China Second University Hospital
Phase 2/3 Recruiting